Elekta appoints Gustaf Salford as Chief Financial Officer

STOCKHOLM, May 10, 2017– Elekta (EKTA-B.ST) announced today that Gustaf Salford has been appointed Executive Vice President and Chief Financial Officer effective July 1, 2017, succeeding Håkan Bergström, who will retire per the same date.

Salford joined Elekta in 2009 and has worked in several financial leadership roles within the company, most recently as Head of Group Business Control. In addition to an MSc degree in Business Administration from the Stockholm School of Economics, Salford brings broad financial experience from among others Boston Consulting Group and Booz Allen Hamilton, as well as intimate knowledge of Elekta and the medical device industry. He has made important contributions to Elekta’s transformation program over the last couple of years.

Elekta President and CEO, Richard Hausmann, says: “I look very much forward to working with Gustaf as our CFO. He has broad financial expertise and shown impressive capabilities in helping us to transform, something he will continue to focus on. I am positive that he will provide us with the financial strategy, vision and leadership required to continue to successfully drive profitable growth at Elekta.”

Hausmann continues: “I would like to take the opportunity to thank Håkan for his excellent support and advice during my first year as CEO at Elekta, as well as his pivotal role in driving Elekta’s transformation. We wish him continued success and well-being.”

Laurent Leksell, Elekta’s Founder and Chairman of the Board of Directors, says: “Håkan has been a key member of our executive team and Elekta’s CFO for over 16 years. He has made countless contributions to Elekta’s development and growth during his tenure. His business acumen and experience in financial matters, combined with his focus on results and value, have been instrumental for Elekta’s success. Our board is very grateful for his contributions and dedication and wishes him all the best in the future.”

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on May 10, 2017. (REGMAR)

About Elekta
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com


About Us

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives. Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.